The U.S. President’s Council of Advisors on Science and Technology (PCAST) has reportedly approved a report that endorses a plan to help drug makers develop new antibiotics, part of an overall effort to address antibiotic-resistant pathogens, i.e., the “superbugs” that infect more than 2 million people in the United States annually and are responsible for some 23,000 deaths. Many of the largest pharmaceutical companies have apparently stopped developing antibiotics given high research and development costs and low returns. In response, PCAST has recommended financial incentives and a national infrastructure for new antibiotic clinical trials that would decrease costs for developers. The advisory group has also called on the U.S. Food and Drug Administration to join the fight against antibiotic resistance. The official report will be issued within the next few weeks. See Fierce Biotech, July 14, 2014.